Has Mandi Greenway Bietz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $901 in general payments to Mandi Greenway Bietz, MD across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mandi Greenway Bietz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mandi Greenway Bietz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mandi Greenway Bietz, MD

Dermatology · Mitchell, SDNPI 1679830905

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $801 of the $901 with a category attached, or 88.9%. Lilly USA, LLC accounts for 65.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $253, 2.5 times the $102 reported in 2019. That places this record below the midpoint for dermatology clinicians in SD, where the typical reported total is $1,250.

$901in general payments, 2019–2025

Across 39 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$587
Johnson & Johnson$115
Bristol Myers Squibb$91
Regeneron Healthcare Solutions, Inc.$37
AbbVie$32
Sun Pharmaceutical Industries Inc.$28
plus $11 from 1 others

What the payments were for

Food & beverage$80189%
Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	29	$587
Johnson & Johnson	2	$115
Bristol Myers Squibb	1	$91
Regeneron Healthcare Solutions, Inc.	2	$37
AbbVie	2	$32
Sun Pharmaceutical Industries Inc.	2	$28
Amgen	1	$11

How this compares

$901 in reported general payments places this provider in the 45th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota →

Medicare billing

Part B allowed, 2024

$1,308

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	19	$374,250
Dupixent PenDupilumab	101	$358,645
Humira(Cf) PenAdalimumab	38	$348,298
Cosentyx Sensoready (2 Pens)Secukinumab	32	$296,333
StelaraUstekinumab	15	$279,412
Taltz AutoinjectorIxekizumab	41	$260,552
OtezlaApremilast	48	$223,383
TremfyaGuselkumab	14	$175,824
RinvoqUpadacitinib	12	$67,982
Dupixent SyringeDupilumab	14	$50,226
Adalimumab-Aacf(Cf) Pen (2 Pk)Adalimumab-Aacf	12	$12,942
Ketoconazole	226	$5,887
Fluocinonide	64	$3,586
Fluorouracil	36	$3,412
Doxycycline Monohydrate	78	$3,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara, Tremfya	$115	$455,23629 claims
AmgenOtezla	$11	$223,38348 claims
AbbVieRinvoq	$32	$67,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Mitchell

Jana JohnsonSioux Falls$2.1M
Ty HansonAberdeen$982K
Lycia ThornburgRapid City$100K
Carmen SchwartzSioux Falls$10K
Michelle DafferDakota Dunes$8K
Sarah SarbackerSioux Falls$8K
Tamara PolingRapid City$7K
Kendra WatsonSioux Falls$6K
Maren GaulRapid City$4K
Jason NobleRapid City$4K

See the full list for South Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →